Loading data for RVMDW — first visit, this takes a few seconds.
Revolution Medicines, Inc. (RVMDW)
NasdaqGS: RVMDW
· Real-Time Price · USD
11.81
+0.34 (2.96%)
At close: Sep 01, 2026, 7:51 PM
The price, the headline numbers and the latest news, in one place.
Revolution Medicines, Inc. (RVMDW) Stock Price, Analysis & Data
No data available
| Bid | 0.35 |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.77B |
| 1.40 | |
| n/a | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.97 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0.39 |
| Volume | 20,815 |
| Avg. Volume (20D) | n/a |
| Open | 0.39 |
| Previous Close | 11.47 |
| Day's Range | 11.30 - 11.81 |
| 52-Week Range | 11.30 - 11.81 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RVMDW
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets an...
IPO Date Jul 17, 2026
Employees 883
Stock Exchange NasdaqGS
Ticker Symbol RVMDW
Website https://www.revmed.com
Financial Performance
In 2025, Revolution Medicines's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.13B, an increase of 88.52%.
Financial StatementsEarnings Surprise
Revolution Medicines has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.